F-6EF 1 e621796_f6ef-freeline.htm

 

As filed with the Securities and Exchange Commission on June 30, 2022 Registration No. 333 -            

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM F-6

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

AMERICAN DEPOSITARY RECEIPTS

 

 

 

Freeline Therapeutics Holdings plc

(Exact name of issuer of deposited securities as specified in its charter)

 

 

 

N/A

(Translation of issuer’s name into English)

 

 

 

England and Wales

(Jurisdiction of incorporation or organization of issuer)

 

 

 

CITIBANK, N.A.

(Exact name of depositary as specified in its charter)

 

 

 

388 Greenwich Street

New York, New York 10013

(877) 248-4237

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

 

 

 

Freeline Therapeutics, Inc.

c/o CT Corporation

Corporation Trust Center

1209 Orange Street

Wilmington, DE 19808

(302) 636-5401

(Address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

Michael Hong, Esq.

Skadden, Arps, Slate, Meagher & Flom LLP

One Manhattan West

New York, New York 10001-8602

 

Herman H. Raspé, Esq.

Patterson Belknap Webb & Tyler LLP

1133 Avenue of the Americas

New York, New York 10036

 

 

 

It is proposed that this filing become effective under Rule 466: ☒ immediately upon filing.
     
  ☐

on (Date) at (Time).

 

If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

 

 

 

CALCULATION OF REGISTRATION FEE

Title of Each Class of
Securities to be Registered		 Amount to be
Registered

Proposed Maximum

Aggregate Price Per

Unit*

Proposed Maximum

Aggregate Offering

Price**

Amount of

Registration Fee

 

American Depositary Shares (“ADS(s)”), each ADS representing the right to one (1) fully paid ordinary share of Freeline Therapeutics Holdings plc. 300,000,000 ADSs $5.00 $15,000,000.00 $1,390.50
 

*Each unit represents 100 ADSs.
**Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

 

 

 

 

This Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

 

ii 

 

 

PART I

 

INFORMATION REQUIRED IN PROSPECTUS

 

Cross Reference Sheet

 

Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

 

Item Number and Caption

  

Location in Form of American

Depositary Receipt (“Receipt”)
Filed Herewith as Prospectus

         
1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
       
2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
         
  Terms of Deposit:    
       
  (i) The amount of deposited securities represented by one American Depositary Share (“ADSs”)   Face of Receipt  - Upper right corner.
         
  (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17) and (18).
         
  (iii) The collection and distribution of dividends   Reverse of Receipt – Paragraph (15).
         
  (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
Reverse of Receipt – Paragraph (18).
         
  (v) The sale or exercise of rights  

Reverse of Receipt – Paragraphs (15) and (17).

         
  (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

Face of Receipt - Paragraphs (3) and (6);

Reverse of Receipt - Paragraphs (15) and (17).

         
  (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
         
  (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
         
  (ix) Restrictions upon the right to deposit or withdraw the underlying securities  

Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9), and (10).

 

 I-1

 

 

Item Number and Caption  

Location in Form of American

Depositary Receipt (“Receipt”)

Filed Herewith as Prospectus

         
  (x) Limitation upon the liability of the Depositary  

Face of Receipt - Paragraph (8);

Reverse of Receipt - Paragraphs (20) and (21).

         
  (xi) Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt – Paragraph (11)
         
Item 2. AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

 

The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

 

 I-2

 

 

PROSPECTUS

 

The Prospectus consists of the form of American Depositary Receipt included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Registration Statement on Form F-6 and is incorporated herein by reference.

 

 I-3

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 3.EXHIBITS

 

(a)Deposit Agreement, dated as of August 11, 2020, by and among Freeline Therapeutics Holdings plc (the “Company”), Citibank, N.A. (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares (“ADSs”) issued thereunder.— Filed herewith as Exhibit (a).

 

(b)(i)Restricted ADS Letter Agreement, dated as of December 7, 2020, by and between the Company and the Depositary. — Filed herewith as Exhibit (b)(i).

 

(b)(ii)At-the-Market Letter Agreement, dated as of November 19, 2021, by and between the Company and the Depositary. — Filed herewith as Exhibit (b)(ii).

 

(b)(iii)Equity Line of Credit ADS Letter Agreement, dated as of March 22, 2022, by and between the Company and the Depositary. — Filed herewith as Exhibit (b)(iii).

 

(c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. — None.

 

(d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. — Filed herewith as Exhibit (d).

 

(e)Certificate under Rule 466. — Filed herewith as Exhibit (e).

 

(f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. — Set forth on the signature pages hereto.

 

 II-1

 

 

Item 4.UNDERTAKINGS

 

(a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

 

(b)If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

 

 II-2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among Freeline Therapeutics Holdings plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 30th day of June, 2022.

 

  Legal entity created by the Deposit Agreement for the issuance of American Depositary Shares, each American Depositary Share representing one (1) fully paid ordinary share of Freeline Therapeutics Holdings plc.
     
  CITIBANK, N.A., solely in its capacity as Depositary
     
  By: /s/ Leslie DeLuca
    Name: Leslie DeLuca
    Title:   Attorney-in-Fact

 

 II-3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, Freeline Therapeutics Holdings plc certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in New York, New York, on June 30, 2022.

 

  Freeline Therapeutics Holdings plc
     
  By: /s/ Michael J. Parini
    Name: Michael J. Parini
    Title:   Chief Executive Officer

 

 II-4

 

 

POWERS OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Stephen P. Diamond, Jr. and Paul M. Schneider to act as his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form F-6 has been signed by the following persons in the following capacities on June 30, 2022.

 

Signature   Title
     
/s/ Michael J. Parini   Chief Executive Officer
Michael J. Parini   (Principal Executive Officer)
     
/s/ Paul M. Schneider   Chief Financial Officer
Paul M. Schneider   (Principal Financial Officer and Principal Accounting Officer)
     
/s/ Chris Hollowood, Ph.D.   Chairman of the Board of Directors
Chris Hollowood, Ph.D.    
     
/s/ Amit Nathwani, M.D.   Director
Amit Nathwani, M.D.    
     
/s/ Martin Andrews   Director
Martin Andrews    
     
/s/ Jeffrey Chodakewitz, M.D.   Director
Jeffrey Chodakewitz, M.D.    

 

 II-5

 

 

Signature   Title
     
/s/ Julia P. Gregory   Director
Julia P. Gregory    
     
/s/ Colin Love   Director
Colin Love    

 

 II-6

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America of Freeline Therapeutics Holdings plc, has signed this registration statement or amendment thereto in New York, New York, on June 30, 2022.

 

FREELINE THERAPEUTICS, INC.  
     
By: /s/ Stephen P. Diamond, Jr.  
  Name: Stephen P. Diamond, Jr.  
  Title: Vice President  

 

 II-7

 

 

Index to Exhibits

 

Exhibit Document

Sequentially

Numbered Page

(a) Deposit Agreement  
(b)(i) Restricted ADS Letter Agreement  
(b)(ii) At-the-Market Letter Agreement  
(b)(iii) Equity Line of Credit ADS Letter Agreement  
(d) Opinion of counsel to the Depositary  
(e) Rule 466 Certification